9-ING-41 in Patients With Advanced Cancers
Public ClinicalTrials.gov record NCT03678883. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
Study identification
- NCT ID
- NCT03678883
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 350 participants
Conditions and interventions
Conditions
- Cancer
- Pancreatic Cancer
- Sarcoma
- Renal Cancer
- Refractory Cancer
- Refractory Neoplasm
- Refractory Non-Hodgkin Lymphoma
- Pancreatic Adenocarcinoma
- Resistant Cancer
- Neoplasm Metastasis
- Neoplasm of Bone
- Neoplasm, Breast
- Neoplasm of Lung
- Neoplasms,Colorectal
- Neoplasms Pancreatic
- Malignant Glioma
- Malignancies
- Malignancies Multiple
- Bone Metastases
- Bone Neoplasm
- Bone Cancer
- Pancreas Cancer
- Pancreatic Neoplasms
- Breast Neoplasms
- Acute T Cell Leukemia Lymphoma
Interventions
- 9-ING-41 Drug
- Gemcitabine - 21 day cycle Drug
- Doxorubicin. Drug
- Lomustine Drug
- Carboplatin. Drug
- Nab paclitaxel. Drug
- Paclitaxel. Drug
- Gemcitabine - 28 day cycle Drug
- Irinotecan Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 4, 2019 (Actual)
- Primary completion
- Jun 2026 (Estimated)
- Completion
- Jun 2026 (Estimated)
- Last update posted
- Apr 3, 2026
2019 – 2026
United States locations
- U.S. sites
- 40
- U.S. states
- 26
- U.S. cities
- 37
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Phoenix | Arizona | 85054 | — |
| Arizona Oncology Associates | Tucson | Arizona | 85704 | — |
| The University of Arizona Cancer Center | Tucson | Arizona | 85719 | — |
| University of California Irvine Health | Orange | California | 92868 | — |
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco | California | 94115 | — |
| Christiana Care Health Services | Newark | Delaware | 19709 | — |
| Sibley Memorial Hospital | Washington D.C. | District of Columbia | 20016 | — |
| Florida Cancer Specialists - South | Fort Myers | Florida | 33901 | — |
| Miami Cancer Institute | Miami | Florida | 33176 | — |
| Florida Cancer Specialists - North | St. Petersburg | Florida | 33705 | — |
| Robert H. Lurie Comprehensive Cancer Center of Northwestern University | Chicago | Illinois | 60611 | — |
| Des Moines Oncology Research Association | Des Moines | Iowa | 50309 | — |
| Kansas University Cancer Center | Kansas City | Kansas | 66160 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| MetroMetro-Minnesota Community Oncology Research Consortium (MMCORC) | Minneapolis | Minnesota | 55416 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89128 | — |
| Morristown Medical Center | Morristown | New Jersey | 07960 | — |
| Capital Health Medical Center/ Hopewell | Pennington | New Jersey | 08534 | — |
| MD Anderson Cancer Center at Cooper | Voorhees Township | New Jersey | 08043 | — |
| Columbia University- Irving Medical Center | New York | New York | 10032 | — |
| Stony Brook University Hospital | Stony Brook | New York | 11794 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| St. Luke's University Health Network | Bethlehem | Pennsylvania | 18015 | — |
| Allegheny Health Network | Pittsburgh | Pennsylvania | 15212 | — |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| Prisma Health Cancer Institute | Greenville | South Carolina | 26905 | — |
| Sanford Research | Sioux Falls | South Dakota | 57105 | — |
| West Cancer Center | Germantown | Tennessee | 38138 | — |
| Baptist Clinical Research Institute | Memphis | Tennessee | 38120 | — |
| Sarah Cannon Research Institute- Tennessee Oncology-Nashville | Nashville | Tennessee | 37203 | — |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232 | — |
| Texas Oncology- Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| UT Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Utah Cancer Specialists | Salt Lake City | Utah | 84124 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | — |
| West Virginia University | Morgantown | West Virginia | 26506 | — |
| UW Carbone Cancer Center | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03678883, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 3, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03678883 live on ClinicalTrials.gov.